• 1. Department of Liver Surgery &  Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
  • 2. West China School of Medicine, Sichuan University, Chengdu 610041, P. R. China;
ZENG Yong, Email: zengyong@medmail.com.cn
Export PDF Favorites Scan Get Citation

Objective To summarize the research progress of four mainstream drug-eluting beads (DEB) in transcathete arterial chemoembolization (TACE) for hepatocellular carcinoma in recent years.Method Through retrieving relevant literatures at home and abroad, the physicochemical properties, pharmacokinetics, effectiveness, and safety of four mainstream DEBs were reviewed.Results The current mainstream DEBs on the market had the characteristics of high drug loading rate and sustained release of drugs, which could reduce the adverse reactions after the embolization to a certain extent. The safety and tolerance of patients receiving DEB-TACE were slightly higher than those receiving traditional TACE (c-TACE). There were no serious complications after the DEB-TACE, but the short-term and long-term efficacies between the two methods were not significantly different.Conclusions At present, most studies believe that the safety and tolerance of DEB are slightly higher than that of c-TACE, but whether the former is more effective than the latter is still controversial at home and abroad, and more high-quality multicenter randomized controlled trials are needed to confirm it.

Citation: JIN Hongyu, YUAN Chi, LIAO Mingheng, WANG Menghua, CAI Qiuyu, LIU Siyu, ZENG Yong. Research progress of drug-eluting beads in arterial chemoembolization for hepatocellular carcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2020, 27(2): 232-238. doi: 10.7507/1007-9424.201905100 Copy

  • Previous Article

    完全经皮二尖瓣植入和主动脉瓣 Valve-in-valve 植入术一例
  • Next Article

    先天性主动脉-肺动脉间隔缺损伴右冠状动脉异常起源于肺动脉一例